Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
United Therapeutics ( (UTHR) ) has issued an update.
On June 26, 2025, United Therapeutics held its Annual Meeting of Shareholders where four key matters were voted on. The shareholders elected directors for a one-year term, approved an advisory resolution on executive compensation, amended the 2015 Stock Incentive Plan, and ratified Ernst & Young LLP as the independent public accounting firm for 2025.
The most recent analyst rating on (UTHR) stock is a Hold with a $319.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics’ strong financial performance and positive earnings call outlook are significant strengths, contributing to a high overall score. The stock’s attractive valuation further supports its potential, despite mixed technical indicators.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
Average Trading Volume: 557,970
Technical Sentiment Signal: Hold
Current Market Cap: $12.9B
See more insights into UTHR stock on TipRanks’ Stock Analysis page.